Drug intelligence / Profile preview

KSP-0243

Development stage: Phase 2
Lead developer: Kissei Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KSP-0243 is an orally administered small molecule drug developed by Kissei Pharmaceutical for the treatment of ulcerative colitis. It is classified as an anti-inflammatory agent, though its precise mechanism of action has not been defined in public sources. The drug has reached Phase 2 clinical trials, where it was evaluated in adults with mild to moderate active ulcerative colitis who had an inadequate response to standard oral 5-ASA therapy. As of March 2025, no orphan drug status or brand name has been reported for this compound.

Other names: KSP 0243KSP0243KSP-0243

Beyond the preview

Go deeper on KSP-0243.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KSP-0243.

Explore the full profile